Clinical Trial Update: A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection with Hemophilia (OP-724-H201) [Phase 2]

View source ↗

Summary

A Phase 2 study of Foscenvivint in liver cirrhosis due to HIV/HCV co-infection with hemophilia is listed as active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cirrhosis

Drugs mentioned

• Foscenvivint

Snippet

Sponsor: Kiminori Kimura, MD | Conditions: Liver Cirrhosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING